J.van, MetsiosG
Statistical analysis GraphPad Prism 7.0 was used for all analyses
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM
While the medication itself does not require tapering from a pharmacological standpoint, the clinical context surrounding discontinuationparticularly the management of underlying conditions like diabetes or obesitydemands careful planning and medical supervision to ensure patient safety and optimize long-term health outcomes
For patients with severe obesity and metabolic disease, this is a giftlife-extending, even lifesaving